Mokou, M.; Lygirou, V.; Angelioudaki, I.; Paschalidis, N.; Stroggilos, R.; Frantzi, M.; Latosinska, A.; Bamias, A.; Hoffmann, M.J.; Mischak, H.;
et al. A Novel Pipeline for Drug Repurposing for Bladder Cancer Based on Patients’ Omics Signatures. Cancers 2020, 12, 3519.
https://doi.org/10.3390/cancers12123519
AMA Style
Mokou M, Lygirou V, Angelioudaki I, Paschalidis N, Stroggilos R, Frantzi M, Latosinska A, Bamias A, Hoffmann MJ, Mischak H,
et al. A Novel Pipeline for Drug Repurposing for Bladder Cancer Based on Patients’ Omics Signatures. Cancers. 2020; 12(12):3519.
https://doi.org/10.3390/cancers12123519
Chicago/Turabian Style
Mokou, Marika, Vasiliki Lygirou, Ioanna Angelioudaki, Nikolaos Paschalidis, Rafael Stroggilos, Maria Frantzi, Agnieszka Latosinska, Aristotelis Bamias, Michèle J. Hoffmann, Harald Mischak,
and et al. 2020. "A Novel Pipeline for Drug Repurposing for Bladder Cancer Based on Patients’ Omics Signatures" Cancers 12, no. 12: 3519.
https://doi.org/10.3390/cancers12123519
APA Style
Mokou, M., Lygirou, V., Angelioudaki, I., Paschalidis, N., Stroggilos, R., Frantzi, M., Latosinska, A., Bamias, A., Hoffmann, M. J., Mischak, H., & Vlahou, A.
(2020). A Novel Pipeline for Drug Repurposing for Bladder Cancer Based on Patients’ Omics Signatures. Cancers, 12(12), 3519.
https://doi.org/10.3390/cancers12123519